Compare Arko Corp. (ARKO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? Arko Corp. trades at $4.39 (market cap $493.06M), while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 272.3× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ARKO | VRTX | |
|---|---|---|
Market Cap | $493.06M | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $529.65 |
52-Week Low | $3.82 | $376.62 |
Enterprise Value | $2.67B | $128.37B |
Dividend Yield | 2.73% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
